Eric M. Dube - 02 May 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
02 May 2025
Net transactions value
-$398,350
Form type
4
Filing time
05 May 2025, 21:53:47 UTC
Previous filing
12 Feb 2025
Next filing
30 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dube Eric M CHIEF EXECUTIVE OFFICER, Director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO /s/ Elizabeth E. Reed, Attorney-in-Fact 05 May 2025 0001763494

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Options Exercise +18,924 +4.5% 438,097 02 May 2025 Direct F1, F2
transaction TVTX Common Stock Sale $398,350 -18,924 -4.3% $21.05 419,173 05 May 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Performance-based restricted stock units Options Exercise $0 -18,924 -50% $0.000000 18,924 02 May 2025 Common Stock 18,924 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.
F2 Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F3 This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.